Literature DB >> 30578405

Reply to Hardalo et al., "Myelosuppression with Oxazolidinones: Are There Differences?"

Aisling R Caffrey1,2,3,4, Erica Yookyung Lee5.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30578405      PMCID： PMC6325224          DOI： 10.1128/AAC.01973-18

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


× No keyword cloud information.
  20 in total

1.  The role of databases in drug postmarketing surveillance.

Authors:  E M Rodriguez; J A Staffa; D J Graham
Journal:  Pharmacoepidemiol Drug Saf       Date:  2001 Aug-Sep       Impact factor: 2.890

2.  Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports.

Authors:  S J Evans; P C Waller; S Davis
Journal:  Pharmacoepidemiol Drug Saf       Date:  2001 Oct-Nov       Impact factor: 2.890

3.  Adverse drug event monitoring at the Food and Drug Administration.

Authors:  Syed Rizwanuddin Ahmad
Journal:  J Gen Intern Med       Date:  2003-01       Impact factor: 5.128

4.  THE ENVIRONMENT AND DISEASE: ASSOCIATION OR CAUSATION?

Authors:  A B HILL
Journal:  Proc R Soc Med       Date:  1965-05

Review 5.  The reporting odds ratio and its advantages over the proportional reporting ratio.

Authors:  Kenneth J Rothman; Stephan Lanes; Susan T Sacks
Journal:  Pharmacoepidemiol Drug Saf       Date:  2004-08       Impact factor: 2.890

6.  Adverse drug event surveillance and drug withdrawals in the United States, 1969-2002: the importance of reporting suspected reactions.

Authors:  Diane K Wysowski; Lynette Swartz
Journal:  Arch Intern Med       Date:  2005-06-27

7.  Thrombocytopenia with Tedizolid and Linezolid.

Authors:  Erica Yookyung Lee; Aisling R Caffrey
Journal:  Antimicrob Agents Chemother       Date:  2017-12-21       Impact factor: 5.191

Review 8.  Statin wars: have we been misled about the evidence? A narrative review.

Authors:  Maryanne Demasi
Journal:  Br J Sports Med       Date:  2018-01-21       Impact factor: 13.800

9.  Hematologic effects of linezolid: summary of clinical experience.

Authors:  Stanton L Gerson; Sheldon L Kaplan; Jon B Bruss; Vu Le; Felix M Arellano; Barry Hafkin; David J Kuter
Journal:  Antimicrob Agents Chemother       Date:  2002-08       Impact factor: 5.191

10.  Replication of the Weber effect using postmarketing adverse event reports voluntarily submitted to the United States Food and Drug Administration.

Authors:  Nicole R Hartnell; James P Wilson
Journal:  Pharmacotherapy       Date:  2004-06       Impact factor: 4.705
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.